Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018

Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’s broad spectrum of activity and equivalence to IV carbapenems CAMBRIDGE, Mass. , June 05, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage

READ FULL TEXT

Leave a Reply

Your email address will not be published.